Experience with the clinical development of influenza vaccines for potential pandemics

John Wood(Women's and Children's Hospital), Audino Podda(Novartis (Italy)), Maria Zambon(Public Health England), Iain Stephenson(Centers for Disease Control and Prevention), K. G. Nicholson(Leicester Royal Infirmary), Diane Major(National Institute for Biological Standards and Control), Robert W. Newman(National Institute for Biological Standards and Control)
Medical Microbiology and Immunology
December 1, 2002
10.1007/s00430-002-0146-x
Cited by 10

Related Papers

Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
|The Lancet|2003|1.1k
Transmission of Equine Influenza Virus to Dogs
|Science|2005|652
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus–induced myeloid-derived suppressor cells in mice and humans
|Journal of Clinical Investigation|2008|349
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
|British Journal of Cancer|2000|208